Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Alpelisib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab + Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Eribulin as a single agent or in combination
h. Everolimus + Exemestane
i. Fulvestrant as a single agent
j. Lapatinib
k. Neratinib
l. Parp Inhibitors (Olaparib/Talazoparib)
m. Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
n. Palbociclib + Fulvestrant
o. Pembrolizumab
p. Platinum (e.g. carboplatin or cisplatin) as a single agent
q. Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
r. Ribociclib + Fulvestrant
s. Sacituzumab Govitecan
t. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
u. Taxane and/or Anthracycline in combination
v. Trastuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Transtuzumab deruxtecan
y. Any other active systemic anti-cancer therapy
Q2. Of the patients treated for breast cancer with Abemaciclib + Aromatase Inhibitor in the past the 3 months, please provide the number of patients with:
a. early/locally advanced breast cancer (Stages 1 to 3B)
b. advanced/metastatic breast cancer (Stages 3C and 4)